Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Homologous Recombination Deficiency (HRD)”

54 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 54 results

Testing effectiveness (Phase 2)Ended earlyNCT03875313
What this trial is testing

Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors

Who this might be right for
Solid TumorClear Cell Renal Cell CarcinomaTNBC - Triple-Negative Breast Cancer+4 more
Calithera Biosciences, Inc 33
Early research (Phase 1)Active Not RecruitingNCT06545942
What this trial is testing

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

Who this might be right for
Advanced Solid TumorMetastatic Solid TumorProstate Cancer+4 more
MOMA Therapeutics 220
Testing effectiveness (Phase 2)Active Not RecruitingNCT06433219
What this trial is testing

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

Who this might be right for
Ovarian Cancer
EMD Serono Research & Development Institute, Inc. 63
Not applicableNot Yet RecruitingNCT06242392
What this trial is testing

The Correlation Between HRD Detection and the Efficacy of PARP Inhibitors in Ovarian Cancer

Who this might be right for
Ovarian Neoplasms
Fujian Cancer Hospital 250
Testing effectiveness (Phase 2)UnknownNCT05201612
What this trial is testing

Pembrolizumab and Olaparib in Homologous-recombination Deficient (HRD) Advanced Colorectal Cancer (CRC).

Who this might be right for
Metastatic Colorectal Cancer
Grupo Espanol Multidisciplinario del Cancer Digestivo 40
Not applicableActive Not RecruitingNCT07303218
What this trial is testing

The HER Project: HRD in EGFR-mutated NSCLC

Who this might be right for
EGFRNon Small Cell Lung CancerHomologous Recombination Deficiency+1 more
IRCCS San Raffaele 100
Testing effectiveness (Phase 2)Ended earlyNCT03367689
What this trial is testing

A Two-stage Simon Design Phase II Study for Non-BRCA MBC Patients With HRD Treated With Olaparib Single Agent

Who this might be right for
Breast Cancer
MedSIR 7
Testing effectiveness (Phase 2)Active Not RecruitingNCT04826341
What this trial is testing

A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors

Who this might be right for
HRD CancerSCLCAdvanced Solid Tumors
National Cancer Institute (NCI) 35
Early research (Phase 1)Looking for participantsNCT06856499
What this trial is testing

Cirtuvivint/Olaparib in Breast Cancer Susceptibility Gene/Homologous Recombination Deficiency Platinum Resistant Ovarian Cancer

Who this might be right for
Endometrioid Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
University of Colorado, Denver 50
Testing effectiveness (Phase 2)Study completedNCT02789332
What this trial is testing

Assessing the Efficacy of Paclitaxel and Olaparib in Comparison to Paclitaxel / Carboplatin Followed by Epirubicin/Cyclophosphamide as Neoadjuvant Chemotherapy in Patients With HER2-negative Early Breast Cancer and Homologous Recombination Deficiency

Who this might be right for
Breast CancerTriple Negative Breast NeoplasmsHRpos Breast Neoplasms+1 more
GBG Forschungs GmbH 107
Not applicableStudy completedNCT03159572
What this trial is testing

Homologous Recombination Inquiry Through Ovarian Malignancy Investigations

Who this might be right for
Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan 996
Testing effectiveness (Phase 2)UnknownNCT04983745
What this trial is testing

Niraparib and Dostarlimab in HRD Solid Tumors

Who this might be right for
Homologous Recombination Deficient Solid Tumors
West Cancer Center 30
Early research (Phase 1)Looking for participantsNCT04890613
What this trial is testing

Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation

Who this might be right for
Advanced Solid Tumor
Senhwa Biosciences, Inc. 52
Large-scale testing (Phase 3)Looking for participantsNCT06580314
What this trial is testing

Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer

Who this might be right for
Fallopian Tube Endometrioid AdenocarcinomaFallopian Tube High Grade Serous AdenocarcinomaFIGO Stage III Ovarian Cancer 2014+6 more
NRG Oncology 880
Testing effectiveness (Phase 2)Active Not RecruitingNCT04666740
What this trial is testing

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy

Who this might be right for
Metastatic Pancreatic Ductal AdenocarcinomaHomologous Recombination Deficiency (HRD)
Memorial Sloan Kettering Cancer Center 63
Large-scale testing (Phase 3)Active Not RecruitingNCT01646034
What this trial is testing

High Dose Chemotherapy in Oligo-metastatic Homologous Recombination Deficient Breast Cancer

Who this might be right for
Breast Cancer
The Netherlands Cancer Institute 74
Testing effectiveness (Phase 2)WithdrawnNCT06120972
What this trial is testing

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency

Who this might be right for
Ovarian Cancer
Alexander B Olawaiye, MD
Testing effectiveness (Phase 2)Study completedNCT02401347
What this trial is testing

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Who this might be right for
Advanced Breast CancerHER2/Neu NegativeTriple-Negative Breast Cancer
Melinda Telli 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT04123366
What this trial is testing

Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

Who this might be right for
Solid Tumors
Merck Sharp & Dohme LLC 300
Not applicableUnknownNCT05044091
What this trial is testing

Homologous Recombination Deficiency in Chinese Ovarian Cancer Patients

Who this might be right for
Ovarian CancerHRDPARP Inhibitor
Xiaoxiang Chen 100
Load More Results